21/12/2004

Director’s Interests

14/12/2004

ReGen Therapeutics Plc Placing raises £1.25m

13/12/2004

Research Update

10/12/2004

ReGen Therapeutics Plc establishes Level-1 American Depositary Receipt Programme (+ FAQ’s as PDF)

10/12/2004

Annual City Presentation

02/12/2004

Preliminary results to 31 December 2003

17/11/2004

Holding(s) in Company

25/10/2004

Completion of Acquisition of Guildford Clinical Pharmacology Unit Limited

19/10/2004

Regen Therapeutics Plc to acquire Guildford Clinical Pharmacology Unit Limited

15/09/2004

Interim Results for the Six Months to 30 June 2004

15/09/2004

Interim Results for the Six Months to 30 June 2004

22/07/2004

Pre-treatment of Cells with Colostrinin™ Prevents Aggregation and Toxicity of Beta Amyloid

10/07/2004

Substantial Shareholding

16/06/2004

In-vivo Study in Chicks shows ReGen’s Colostrinin™ enhances memory

09/06/2004

Reduction of Memory Impairment

20/05/2004

US Laboratory Studies show the potential of ReGen’s Colostrinin™ to impact pathologies involved in Alzheimer’s disease

20/04/2004

AGM Statement

20/04/2004

Results of Annual General Meeting

05/04/2004

Research Update

05/04/2004

New York visit by ReGen Chairman

19/03/2004

Notice of AGM

19/03/2004

Research Update

17/03/2004

Colostrinin (1) (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer’s disease

17/03/2004

Colostrinin™ Clinical Study is published in Journal of Alzheimer’s Disease

13/02/2004

Notification of Change in Interests of Directors

12/02/2004

ReGen Therapeutics Plc Placing raises £500,000

12/02/2004

Preliminary results to 31 December 2003

26/01/2004

Disclosure of Notifiable Interest – Disposal of Shares